The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis [11]

Leukemia

Volumn 21, Issue 10, 2007, Pages 2210-2212

  Pemmaraju, N ^a   Moliterno, A R ^a   Williams, D M ^a   Rogers, O ^a   Spivak, J L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; GENOMIC DNA; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTERY THROMBOSIS; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; DISEASE COURSE; DISEASE DURATION; DRUG USE; ERYTHROMELALGIA; FEMALE; GENDER; GENE MUTATION; GENETIC HETEROGENEITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; LEUKOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MIGRAINE; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; SEX DIFFERENCE; STROKE; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 34548242134     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404755     Document Type: Letter

References (8)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
3. Moliterno AR, Williams DM, Rogers O, Spivak IL. Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between quantitative JAK2 V617F and Mpl expression. Blood 2006; 108: 3913-3915.
4. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-3682.
5. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al. JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-213.
6. el Kassar N, Hetet G, Briere J, Grandchamp B. Clonality analysis of hematopoiesis in essential thrombocythemia: Advantages of studying T lymphocytes and platelets. Blood 1997; 89: 128-134.
7. Kiladjian JJ, Elkassar N, Cassinat B, Hetet G, Giraudier S, Balitrand N et al. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders. Leukemia 2006; 20: 1181-1183.
8. Antonioli E, Guglielmelli P, Pancrazzi A, Bogani C, Verrucci M, Ponziani V et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847-1849.